Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16215917 | 0.82 | GBA1 (0.55) | GBA1MCHR1GRM2KDM4EALDH1A1 | |
| SCHEMBL12089150 | 0.81 | GBA1 (0.44) | GBA1MCHR1GRM2MBOAT4KDM4E | |
| SCHEMBL1241260 | 0.80 | TAAR1 (0.52) | GBA1MCHR1GRM2TAAR1SLC6A2 | |
| SCHEMBL19739531 | 0.78 | ALDH1A1 (0.44) | GBA1MCHR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13577890 | 0.77 | CCR1 (0.44) | LTA4HKDM4EALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL684128 | 0.76 | — | — | |
| SCHEMBL529043 | 0.75 | LTA4H (0.37) | LTA4HKDM4EALDH1A1SLC6A4CHRNB2 | |
| SCHEMBL30911483 | 0.75 | LTA4H (0.37) | LTA4HALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11956156 | 0.75 | ESR1 (0.49) | LTA4HKDM4EALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL11955565 | 0.73 | HRH3 (0.47) | KDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2018086589-A1 | 1,5,7-TRI-SUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES | 上海海雁医药科技有限公司 | 2018-05-17 | — | — | WO | disclosed |
| EP-2953944-B1 | PYRIDAZINONE-AMIDES DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20170071936-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-9567320-B2 | Pyridazinone-amides derivatives | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20150376167-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2953944-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014121931-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| CN-101128461-B | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI | 2010-12-22 | — | — | CN | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| CN-101128461-A | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI (US) | 2008-02-20 | — | — | CN | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071936-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | CNKSR1, SSB, NQO2 | GBA1 1118/4885MCHR1 3366/4885LTA4H 2186/4885 |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | CDK2, CCNI, CDK20 | GBA1 4151/4885MCHR1 4474/4885LTA4H 4238/4885 |
| US-20150376167-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | CNKSR1, SSB, NQO2 | GBA1 1118/4885MCHR1 3366/4885LTA4H 2186/4885 |
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | GBA1 3563/4885MCHR1 313/4885LTA4H 1892/4885 |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | GBA1 4653/4885MCHR1 338/4885LTA4H 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.